Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06867471

Effects of Exogenous Ketosis on Proteinuria and Renal Function in Patients with Chronic Kidney Disease and Polycystic Kidney Disease

Led by Gødstrup Hospital · Updated on 2025-03-10

43

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

Researchers are evaluating the effects of exogenous ketosis on proteinuria and kidney function in patients with chronic kidney disease (CKD) and polycystic kidney disease (PKD). This randomized, placebo-controlled, double-blinded crossover study aims to explore if ketone bodies (Ketone-IQ) can reduce urine albumin to creatinine ratio (ACR) and glomerular filtration rate (GFR), addressing the need for additional treatments beyond current options like ACE inhibitors, ARBs, and SGLT2 inhibitors. The study involves patients with proteinuric kidney disease and PKD, focusing on the therapeutic potential of ketosis in these populations. Participants will receive ketone bodies (Ketone-IQ) and a placebo drink in a randomized order, each for four weeks, separated by a two-week wash-out period. Ketone-IQ is given twice daily as a drink containing Ketone Diol, R-1,3-butanediol, dosed at 400 mg/kg before bedtime and 200 mg/kg at least six hours earlier. The placebo drink is matched in taste and volume. The crossover design allows each participant to serve as their own control, enhancing the study's evaluation of ketone bodies' impact on kidney function. During the study, measurements will be taken on the last day of each treatment period, including 24-hour urine protein levels (proteinuria), GFR, aldosterone, Beta-hydroxybutyrate, renal tubular transport proteins, ambulatory blood pressure, sodium and potassium excretion, peripheral vascular resistance, heart rate, pulse wave velocity, and renin levels. The study includes safety monitoring and aims to provide comprehensive data on how exogenous ketosis affects kidney health over the treatment periods. Participants are involved for approximately ten weeks including treatment and wash-out phases.

CONDITIONS

Brief Title

Effects of Exogenous Ketosis on Proteinuria and Renal Function

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 years or older
  • For proteinuric kidney disease: urine albumin to creatinine ratio (ACR) between 200 mg/g and 3000 mg/g
  • For all participants: estimated glomerular filtration rate (eGFR) greater than 30 ml/min/1.73m2
  • Treatment with Renin-Angiotensin System (RAS) blockers for at least 4 weeks prior to inclusion
  • For proteinuric kidney disease patients: treatment with SGLT-2 inhibitors for at least 4 weeks prior to inclusion
  • Safe contraception use for women of childbearing age
  • Prior diagnosis of polycystic kidney disease (for PKD group)
Not Eligible

You will not qualify if you...

  • Type 1 diabetes mellitus
  • Heart failure
  • Liver disease
  • Kidney transplant
  • Malignant diseases except skin cancer
  • Recent acute myocardial infarction or stroke within 3 months before inclusion
  • Pregnancy or breastfeeding
  • Alcohol or drug abuse
  • Periodic fasting within 4 weeks before inclusion
  • Routine ketogenic diet intake within 4 weeks before inclusion
  • Treatment with nitrate

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 4 weeks per treatment period with a 2-week washout in between

Participants receive two different drinks in a randomized order: Ketone-IQ and a placebo drink. Each drink is taken twice a day for four weeks with a two-week washout period between treatments.

Visits on the last day of each 4-week treatment period for assessments

Trial Site Locations

Total: 1 location

1

University Clinic in Nephrology and Hypertension, Gødstrup Region Hospital

Herning, Jutland, Denmark, 7400

Actively Recruiting

Loading map...

Research Team

T

Trine Z Lyksholm, MD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

PREVENTION

Number of Arms

2

Similar Trials

A Smart Phone Application to Improve Adoption of the 2024 Ki...

Chronic Kidney Disease

Actively Recruiting

2 locations

An 18-month Open-label Study of Oral Finerenone with ACE Inh...

Chronic Kidney Disease

Actively Recruiting

179 locations

A 6-month Study Evaluating Finerenone with ACE Inhibitor or ...

Chronic Kidney Disease

Actively Recruiting

164 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here